Real-world efficacy of proactive maintenance treatment with delgocitinib ointment twice weekly in adult patients with atopic dermatitis.
JAK inhibitor
atopic dermatitis
corticosteroid
delgocitinib
stratum corneum hydration
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
11
04
2022
received:
09
02
2022
accepted:
17
04
2022
pubmed:
21
4
2022
medline:
15
7
2022
entrez:
20
4
2022
Statut:
ppublish
Résumé
Previous studies have shown the efficacy of delgocitinib (DEL) ointment, a topical Janus kinase inhibitor, against atopic dermatitis (AD). However, there is no available information regarding the efficacy of DEL ointment in maintaining remission. Data of patients with AD who received remission maintenance therapy twice weekly with DEL or topical corticosteroid (TCS) on the affected skin of each upper limb were extracted from the medical records. Efficacy was assessed based on changes in pruritus numerical rating scale (NRS) score, stratum corneum hydration (SCH), erythema index (EI). Of 25 patients, four patients (16%) had eczema flare-ups on the TCS side and eight patients (32%) on the DEL side. The extent of change in each parameter between TCS- and DEL-treated areas of the skin did not differ significantly. The mean changes in the NRS and EI showed a slight improvement on the side treated with TCS and were slightly worse on the side treated with DEL. However, the SCH of the DEL group was maintained, while that of the TCS group worsened. TCS is more likely to be effective than DEL in terms of remission maintenance therapy. However, topical DEL is as effective as topical steroid in the maintenance therapy of AD in dry skin patients.
Substances chimiques
Dermatologic Agents
0
Emollients
0
Glucocorticoids
0
Ointments
0
Pyrroles
0
delgocitinib
9L0Q8KK220
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15526Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Dattola A, Bennardo L, Silvestri M, Nisticò SP. What's new in the treatment of atopic dermatitis? Dermatol Ther. 2019;32(2):2-5.
Leung DYM, Paller AS, Guttman-Yassky E. New therapies for atopic dermatitis: how will they impact skin care? Ann Allergy Asthma Immunol. 2022;000:2-3.
Yang X, Kambe N, Takimoto-Ito R, Kabashima K. Advances in the pathophysiology of atopic dermatitis revealed by novel therapeutics and clinical trials. Pharmacol Ther. 2021;224:107830.
Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14):1483-1494.
Katoh N, Ohya Y, Ikeda M, et al. Clinical practice guidelines for the management of atopic dermatitis 2018. J Dermatol. 2019;46(12):1053-1101.
Pernis AB, Rothman PB. JAK-STAT signaling in asthma. J Clin Invest. 2002;109(10):1279-1283.
Clarysse K, Pfaff CM, Marquardt Y, et al. JAK1/3 inhibition preserves epidermal morphology in full-thickness 3D skin models of atopic dermatitis and psoriasis. J Eur Acad Dermatol Venereol. 2019;33(2):367-375.
Nakashima C, Otsuka A, Kabashima K. Interleukin-31 and interleukin-31 receptor: new therapeutic targets for atopic dermatitis. Exp Dermatol. 2018;27(4):327-331.
Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-132.
Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part i. J Eur Acad Dermatology Venereol. 2012;26(8):1045-1060.
Saito R, Tanaka A, Hiragun T, et al. Reduction of serum thymus and activation-regulated chemokine after short-term intensive therapy may predict better prognosis of moderate to severe atopic dermatitis. J Dermatol. 2019;46(12):e486-e487.
Mayba JN, Gooderham MJ. Review of atopic dermatitis and topical therapies. J Cutan Med Surg. 2017;21(3):227-236.
Wollenberg A, Ehmann LM. Long term treatment concepts and proactive therapy for atopic eczema. Ann Dermatol. 2012;24(3):253-260.
Russo F, Milanesi N, Iannone M, et al. Tuscan consensus on the diagnosis, treatment and follow-up of adult atopic dermatitis. G Ital di Dermatologia e Venereol. 2020;155(3):253-260.
Hajar T, Leshem YA, Hanifin JM, et al. A systematic review of topical corticosteroid withdrawal (“steroid addiction”) in patients with atopic dermatitis and other dermatoses. J Am Acad Dermatol. 2015;72(3):541-549.
Russell JJ. Topical tacrolimus: a new therapy for atopic dermatitis. Am Fam Physician. 2002;66(10):1899-1902.
Nakagawa H. Comparison of the efficacy and safety of 0.1% tacrolimus ointment with topical corticosteroids in adult patients with atopic dermatitis. Clin Drug Investig. 2006;26(5):235-246.
Worm M, Bauer A, Elsner P, Mahler V, Molin S, Nielsen TSS. Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double-blind, vehicle-controlled phase IIa study. Br J Dermatol. 2020;182(5):1103-1110.
Nakagawa H, Nemoto O, Yamada H, Nagata T, Ninomiya N. Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis. J Dermatol. 2018;45(6):701-709.
Nakagawa H, Nemoto O, Igarashi A, et al. Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis. J Allergy Clin Immunol. 2019;144(6):1575-1583.
Nakagawa H, Nemoto O, Igarashi A, Saeki H, Kaino H, Nagata T. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. J Am Acad Dermatol. 2020;82(4):823-831.
Egawa M, Tagami H. Comparison of the depth profiles of water and water-binding substances in the stratum corneum determined in vivo by Raman spectroscopy between the cheek and volar forearm skin: effects of age, seasonal changes and artificial forced hydration. Br J Dermatol. 2008;158(2):251-260.
Yang J, Tu Y, Man M-Q, et al. Seasonal variations of epidermal biophysical properties in Kunming, China: a self-controlled cohort study. Skin Res Technol. 2020;26(5):702-707.
Tanimoto A, Ogawa Y, Oki C, et al. Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. Inflamm Res. 2015;64(1):41-51.
Schmitt J, Von Kobyletzki L, Svensson Å, Apfelbacher C. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2011;164(2):415-428.
Wollenberg A, Bieber T. Proactive therapy of atopic dermatitis - an emerging concept. Allergy Eur J Allergy Clin Immunol. 2009;64(2):276-278.
Anagawa-Nakamura A, Ryoke K, Yasui Y, Shoda T, Sugai S. Effects of Delgocitinib ointment 0.5% on the Normal mouse skin and epidermal tight junction proteins in comparison with topical corticosteroids. Toxicol Pathol. 2020;48(8):1008-1016.